Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial uncoupling protein 4 (UCP4, SLC25A27) is a brain-enriched member of the mitochondrial anion carrier protein (MACP) family that mediates proton leak across the inner mitochondrial membrane, uncoupling oxidative phosphorylation from ATP synthesis and regulating energy dissipation as heat[1][5][3]. UCP4 plays an important role in neuronal cells by modulating the mitochondrial membrane potential, reducing oxidative stress, and protecting against metabolic stress and neurotoxins[3][7]. UCP4 expression is largely restricted to brain tissue and is developmentally regulated. Genetic variants in SLC25A27 have been associated with neurodegenerative conditions, suggesting that UCP4-mediated regulation of mitochondrial function is relevant to diseases such as Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and psychiatric disorders[2][3]. No approved drugs directly target UCP4.
Not applicable, as no clinically used drug is confirmed to directly target UCP4. Drugs or small molecules would theoretically modulate its uncoupling activity or expression, affecting mitochondrial proton gradient, ROS generation, or neuronal survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial uncoupling protein 4 (UCP4).